alpha-msh

α-MSH (alpha-melanocyte-stimulating hormone)

α-MSH is a 13-amino-acid peptide derived by post-translational cleavage of proopiomelanocortin (POMC). It signals through melanocortin receptors (MC1R–MC5R) to coordinate melanogenesis, appetite suppression, thermoregulation, and broad anti-inflammatory responses. In the aging context, α-MSH is most relevant as (1) the parent peptide for KPV — its anti-inflammatory C-terminal tripeptide — and (2) the endogenous template for the synthetic analog Melanotan II. POMC neuron tone in the hypothalamic arcuate nucleus declines with age, reducing α-MSH signalling to the melanocortin-4 receptor and contributing to age-associated energy dysregulation.

Identity

• UniProt (parent precursor): P01189 (POMC_HUMAN); α-MSH itself is not assigned a separate UniProt accession — it is a processed peptide chain annotated within POMC
• NCBI Gene (POMC): 5443
• HGNC: 9201 (symbol: POMC)
• Ensembl: ENSG00000115138
• Sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ (Ac-SYSMEHFRWGKPV-NH₂)
• Residue positions within POMC: 138–150 (13 residues; positions as annotated in UniProt P01189)
• Molecular weight: ~1,665 Da (free acid); amidated at C-terminus, acetylated at N-terminus in the biologically active form
• Mouse ortholog: Pomc (NCBI Gene 18976); ~92% sequence identity in the α-MSH region

POMC processing and α-MSH generation

α-MSH is one of several biologically active peptides encoded by a single POMC precursor (267 aa in human). Tissue-specific expression of prohormone convertases (PC1/3 and PC2) determines which peptides are liberated ¹:

Tissue	Convertases expressed	Primary α-MSH-relevant products
Anterior pituitary	PC1/3	ACTH (dominant; α-MSH precursor)
Intermediate pituitary / brain	PC1/3 + PC2	α-MSH, β-MSH, γ-MSH, CLIP
Hypothalamic arcuate nucleus	PC1/3 + PC2	α-MSH (released onto MC4R/MC3R)
Skin keratinocytes / melanocytes	PC1/3	α-MSH (autocrine; UV-induced)
Immune cells	PC1/3	α-MSH (immunomodulation)

Key co-products from the same POMC precursor:

• ACTH (residues 138–176): stimulates adrenal cortisol secretion via MC2R
• β-endorphin (residues 237–267): endogenous opioid
• β-MSH (residues 217–234): melanocortin receptor agonist (rodent/primate)
• γ-MSH (residues 77–87): MC3R preferring; natriuresis, energy balance

The final processing steps converting ACTH(1–13) to α-MSH involve cleavage by PC2 followed by N-terminal acetylation (by N-acetyltransferase) and C-terminal amidation (by PAM, peptidylglycine α-amidating monooxygenase). Both modifications are required for full biological potency ¹.

Melanocortin receptor subtypes and signalling

α-MSH binds all five melanocortin receptors (MC1R–MC5R), which are Gαs-coupled GPCRs signalling primarily through cAMP/PKA. Receptor selectivity profile:

Receptor	α-MSH affinity	Primary tissue	Key functions
MC1R	High (Ki ~1 nM)	Skin melanocytes, immune cells	Melanogenesis; anti-inflammatory
MC2R	Does NOT bind	Adrenal cortex	ACTH-specific cortisol secretion
MC3R	Moderate	Hypothalamus, gut, immune	Energy balance; anti-inflammatory; natriuresis
MC4R	High (Ki ~1–5 nM)	Hypothalamus, brainstem	Appetite suppression; energy expenditure; thermoregulation
MC5R	Low–moderate	Exocrine glands, immune cells	Sebaceous secretion; immune modulation

Downstream: cAMP → PKA → CREB phosphorylation; also MAPK pathway modulation (receptor- and context-dependent) ².

Functions

Melanogenesis and pigmentation (MC1R)

α-MSH is the principal physiological stimulus for melanin synthesis in skin. Binding MC1R in melanocytes activates cAMP → PKA → MITF → tyrosinase transcription → eumelanin production. This UV-protective response is exploited therapeutically by the synthetic analogs afamelanotide (Scenesse) and Melanotan II.

Appetite suppression and energy balance (MC4R)

POMC neurons in the hypothalamic arcuate nucleus (ARC) project to the paraventricular nucleus (PVN) and release α-MSH onto MC4R, reducing food intake and increasing energy expenditure. Agouti-related protein (AgRP) is an endogenous MC4R inverse agonist that competes with α-MSH; the AgRP/POMC balance is a central regulator of energy homeostasis. MC4R loss-of-function mutations cause severe monogenic obesity, representing the most common single-gene form of human obesity.

Anti-inflammatory effects (MC1R, MC3R, MC4R)

α-MSH suppresses inflammatory signalling through multiple mechanisms ^{1 2}:

• NF-κB pathway: inhibits IκB kinase activation → reduced IκB degradation → NF-κB nuclear translocation blocked → reduced TNF-α, IL-1β, IL-6 production; additionally, α-MSH promotes IRAK-M (the inhibitory decoy for IRAK-1) in macrophages stimulated via TLR4, blocking signal transduction at an early step
• MAP kinase: attenuates JNK and p38 MAPK phosphorylation in macrophages and epithelial cells; ERK1/2 phosphorylation also attenuated (confirmed in intestinal epithelial cells)
• cAMP/PKA: raises intracellular cAMP, activating PKA and potentially CREB-driven anti-inflammatory gene programmes
• JAK/STAT: JAK/STAT activation has been reported upon MC5R stimulation; SOCS3 induction by α-MSH (via STAT3) constitutes a negative-feedback anti-inflammatory mechanism
• Fever suppression: acts in the brain’s preoptic area (MC4R) to antagonise pyrogen-induced fever; reduces IL-1β and prostaglandin E₂ centrally

These properties are preserved in C-terminal fragments — notably the tripeptide KPV (Lys-Pro-Val, residues 11–13 of α-MSH) — that act independently of melanocortin receptor binding ³.

Thermoregulation

MC4R activation in the hypothalamus increases sympathetic outflow to brown adipose tissue, promoting thermogenesis. This is distinct from the MC4R appetite-suppression pathway but uses the same receptor.

Vascular function

α-MSH promotes endothelial nitric oxide production through MC1R on endothelial cells, improving vasodilatation and protecting against endothelial dysfunction in rodent models. Mechanistically, α-MSH increases eNOS mRNA expression and eNOS phosphorylation at Ser1177 via MC1R in human endothelial cells (HUVECs); Mn-SOD expression is also upregulated, reducing ROS. In vivo in 10-month-old C57BL/6N mice, acute NDP-α-MSH (0.3 mg/kg i.p.) improved endothelium-dependent vasodilatation in the aorta; chronic MT-II (0.3 mg/kg/day, 3 weeks) in diet-induced obese mice improved aortic and mesenteric artery function ⁴. The aging relevance of this pathway is unexplored in humans. needs-human-replication

KPV: the receptor-independent anti-inflammatory fragment

The C-terminal tripeptide Lys-Pro-Val (KPV) corresponds to α-MSH residues 11–13 and retains “almost all of the anti-inflammatory capacity of the full hormone” in cell and rodent models ³. Critically, KPV’s anti-inflammatory activity is melanocortin-receptor-independent — it does not measurably bind MC1R–MC5R at physiological concentrations; it enters intestinal epithelial cells via the PepT1 di/tripeptide transporter (SLC15A1) and directly inhibits NF-κB and MAP kinase from within the cell ⁵. See kpv for full pharmacology.

Therapeutic analogs

Agent	Structure	FDA status	Mechanism
Afamelanotide (Scenesse)	Linear α-MSH analog: [Nle4,D-Phe7]-α-MSH	FDA-approved 2019 (EPP)	MC1R agonist; UV-independent melanogenesis
Melanotan II	Cyclic: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂	Not approved; investigational	Broad MCR agonist; tanning + appetite + erectile
KPV	Tripeptide: H-Lys-Pro-Val-OH	Preclinical	Receptor-independent NF-κB inhibition

Afamelanotide is FDA-approved under the orphan-drug pathway for increasing pain-free light exposure in erythropoietic protoporphyria (EPP), with the primary mechanism being UV-independent skin darkening via MC1R that reduces the phototoxic threshold ⁶.

Druggability-tier rationale (tier 1): A clinical drug (afamelanotide/Scenesse) exists that targets this peptide’s primary receptor (MC1R) and is FDA-approved (2019). However, the aging-context tier note is: no aging-indication drug exists against α-MSH or its receptors; tier-1 designation reflects the pharmacological tractability of the melanocortin system rather than an aging-approved indication.

Aging context: POMC neuron decline

Hypothalamic POMC neurons decline with age, reducing α-MSH tone to the melanocortin-4 receptor and contributing to age-associated weight gain, adiposity, and metabolic inflexibility. Evidence from mice:

• Hypothalamic SIRT1 protein expression declines with age in the arcuate nucleus; conditional SIRT1 overexpression specifically in POMC neurons (Rosa26-Sirt1 knock-in × Pomc-Cre; mixed 129/J × C57BL/6J background) prevents age-related weight gain in male mice via increased energy expenditure and sympathetic outflow to adipose tissue, with improved leptin sensitivity; food intake was not reduced (energy expenditure, not intake suppression, was the primary driver); effect was male-specific in the reported data ⁷. needs-human-replication
• POMC neuron numbers and peptide content decrease in aged rodent hypothalami, though the human equivalent is not well-characterised. needs-human-replication

Aging-specific evidence for α-MSH itself (as opposed to POMC neuron biology broadly) is thin. α-MSH circulating levels have not been robustly characterised across aging cohorts with appropriate pre-analytical controls, and no interventional human study has targeted α-MSH or its receptors specifically for an aging indication.

Dimension	Status
Pathway conserved in humans?	yes (POMC/MCR system highly conserved)
POMC neuron decline phenotype conserved in humans?	partial (rodent data strong; human ARC aging data sparse)
Replicated in humans for aging endpoints?	no

needs-human-replication — Arcuate POMC neuron decline with aging has not been quantitatively demonstrated in human post-mortem ARC tissue at the same resolution as rodent data.

Anti-inflammatory context: chronic inflammation and hallmarks

Although chronic-inflammation is a central aging hallmark (inflammaging), α-MSH’s anti-inflammatory effects have not been demonstrated in human aging populations — evidence is confined to acute inflammatory disease models (sepsis, IBD, arthritis in rodents) and cell culture ². Whether restoring α-MSH tone or targeting MCRs pharmacologically reduces chronic low-grade inflammation in older humans remains an open question. needs-human-replication

Pathway membership

• melanocortin-system — canonical POMC → α-MSH → MC1/3/4/5R axis (implicit stub; page not yet created)
• pomc-processing — endoproteolytic processing by PC1/3 + PC2 (implicit stub)
• nf-kb — α-MSH suppresses NF-κB activation
• insulin-igf1 — overlapping energy-balance regulation via hypothalamic MC4R

Key interactors and related entities

• pomc — parent precursor protein (implicit stub; no separate protein page yet)
• kpv — C-terminal tripeptide fragment; receptor-independent anti-inflammatory
• melanotan-ii — synthetic cyclic analog; broad MCR agonist; not approved
• mc1r — primary pigmentation receptor (implicit stub)
• mc4r — appetite/energy receptor (implicit stub)
• mc3r — anti-inflammatory + energy balance receptor (implicit stub)
• agrp — endogenous MC4R inverse agonist; counterbalances α-MSH in ARC (implicit stub)

Limitations and gaps

• needs-canonical-id — α-MSH has no independent UniProt accession; it is a processed chain within POMC (P01189). Frontmatter uniprot: field is set to the POMC precursor entry per wiki convention for peptide hormones.
• needs-human-replication — POMC neuron decline with aging demonstrated in rodents; human arcuate nucleus aging data lacking.
• needs-human-replication — Anti-inflammatory effects of α-MSH replicated extensively in rodent acute-inflammation models; no human aging RCT exists.
• needs-tissue-expression-data — GTEx aging correlation for POMC transcript not computed; α-MSH is a post-translational product requiring separate assay (mass spectrometry or RIA).
• long-term-unknown — No long-term pharmacological data on MC1R or MC4R agonism for aging-relevant outcomes in humans.
• melanocortin-system and pomc-processing pathway pages are implicit stubs — these pathways are referenced but no dedicated wiki pages exist yet.
• pomc, mc1r, mc3r, mc4r, agrp are implicit stubs — protein pages for these entities do not yet exist.

Footnotes

Footnotes

1. doi:10.1210/er.2007-0027 · Brzoska T, Luger TA, Maaser C, Abels C, Böhm M · Endocrine Reviews 2008 · review · n=N/A · canonical comprehensive review of α-MSH and related tripeptides: biochemistry, anti-inflammatory mechanisms, in-vivo rodent efficacy, therapeutic perspective · cited_by: 318 · locally: not_oa (bronze OA URL resolves behind Cloudflare; cannot verify; no-fulltext-access for Brzoska 2008-derived claims) ↩ ↩² ↩³

2. doi:10.1100/tsw.2010.173 · Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S · The Scientific World Journal 2010 · review · melanocortin system in control of inflammation; covers MC1–MC5 receptor subtypes, NF-κB/MAPK suppression via IκB protection + PKA activation + IRAK-1/IRAK-M pathway, JAK/STAT activation at MC5R, and therapeutic scope across sepsis/IBD/RA/CNS injury · anti-inflammatory signalling primarily via MC1 and MC3 in peripheral cells, MC4 in brain · cited_by: 174 · locally: completed (PDF available) ↩ ↩² ↩³

3. doi:10.1007/978-1-4419-6354-3_8 · Brzoska T, Böhm M, Lügering A, Loser K, Luger TA · Adv Exp Med Biol 2010 · review · chapter on terminal-signal KPV anti-inflammatory activity beyond the pharmacophore; establishes KPV receptor-independence · cited_by: 34 · locally: not_oa ↩ ↩²

4. doi:10.1093/cvr/cvs335 · Rinne P, Nordlund W, Heinonen I et al. · Cardiovascular Research 2013 · in-vivo (mouse: C57Bl/6N acute; DIO-obese chronic; transgenic MSH-OE) + in-vitro (HUVEC; EA.hy926) · n=8–14 per group (vascular reactivity); n=4–8 (Langendorff coronary) · α-MSH enhances endothelium-dependent vasodilatation via MC1R → eNOS Ser1177 phosphorylation + Mn-SOD upregulation; protects against endothelial dysfunction in aged and obese mice · cited_by: 22 · locally: completed (PDF available) ↩

5. doi:10.1053/j.gastro.2007.10.026 · Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D · Gastroenterology 2008 · in-vivo (mouse colitis, female C57BL/6, 8 wk) + in-vitro · n=10 mice/group (DSS model); n=10 mice/group (TNBS model) · PepT1-mediated KPV cellular uptake reduces intestinal inflammation via NF-κB and MAPK suppression; KPV Km in Caco2-BBE ≈160 μmol/L · cited_by: 120 · locally: completed (PDF available) ↩

6. doi:10.36849/jdd.5526 · Wu J, Cotliar R · Journal of Drugs in Dermatology 2021 · review · afamelanotide (Scenesse) FDA approval for EPP; mechanism and clinical trial summary · cited_by: 10 · locally: not_oa ↩

7. doi:10.1007/s00125-013-3140-5 · Sasaki T, Kikuchi O, Shimpuku M et al. · Diabetologia 2014 · in-vivo (mouse; Rosa26-Sirt1 KI × Pomc-Cre; mixed 129/J × C57BL/6J background) · hypothalamic SIRT1 protein declines with age in ARC; conditional SIRT1 overexpression in POMC neurons (Pomc-Cre) prevents age-related weight gain in males via increased energy expenditure + sympathetic outflow to adipose tissue (not via reduced food intake) + improved leptin sensitivity · cited_by: 90 · locally: completed (PDF available) ↩